This shareable PDF can be hosted on any platform or network and is fully compliant with publisher copyright.
This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.
If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.
This page is a summary of: Evaluation of maintenance treatment with PARP inhibitors in ovarian carcinoma patients responding to platinum therapy: Use of restricted mean survival time as an index of efficacy, International Journal of Clinical Pharmacology and Therapeutics, January 2022, Dustri-Verlgag Dr. Karl Feistle,
DOI: 10.5414/cp204113.
You can read the full text:
The following have contributed to this page
